Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
The NHS access journey, should CagriSema receive approval, would then follow a separate NICE appraisal process the same pathway that Wegovy and Mounjaro have navigated
Stem cell therapy is an advanced regenerative treatment that uses the bodys own ability to heal itself
Talk with the AgeRejuvenation team about a Semax Peptide Therapy plan built around your labs and goals.
